Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Organisation › Details

PhoreMost Ltd.

PhoreMost has developed a next-generation phenotypic drug discovery technology called SITESEEKER®, which uses the power of live-cells to discern the best new targets for future therapy and crucially, how to drug them. Based on ‘Protein Interference’ (PROTEINi®); a new genome-wide target identification & validation platform created by PhoreMost, SITESEEKER® can now systematically reveal critical druggable target-sites in any particular disease setting and then convert this information rapidly into novel small-molecule therapeutics. Using SITESEEKER®, PhoreMost is exclusively developing first-in-class targets for a range of unmet diseases and will collaborate with other pharmaceutical companies also wishing to engage in ‘Drugging the Undruggable®’. www.phoremost.com *

 

Period Start 2015-04-07 established
Products Industry drug discovery
  Industry 2 Siteseeker® drug target discovery technology
Persons Person Torrance, Chris (PhoreMost 201504– CEO + Co-founder before Horizon Discovery Co-founder + Vernalis)
  Person 2 Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)
     
Region Region Babraham, Cambridgeshire
  Country United Kingdom (GB)
  Street Building B580, Room 2011
Babraham Research Campus
  City CB22 3AT Babraham, Cambridgeshire
  Tel +44-1223-804163
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: PhoreMost Ltd.. (3/10/16). "Press Release: PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging". Cambridge.
     
   
Record changed: 2020-11-10

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for PhoreMost Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80




» top